Sobi announces a new research collaboration on the development of Gamifant in sepsis, which is to be presented at the ISICEM congress: Stockholm Thursday, March 20, 2025, 12:00 Hr ...
A study from St. Jude Children’s Research Hospital reveals that the protein VDAC2 acts as a “signal jammer” in tumors, ...
The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS ...
Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular ...
Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFN?)-driven sepsis (IDS ...
Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...
SAN DIEGO, Calif. (Ivanhoe Newswire) - A breakthrough in bladder cancer treatment is helping to save more lives. The American Cancer Society estimates that 83,000 new cases of bladder cancer will be ...
St. Jude researchers identified a protein, voltage-dependent anion channel 2 (VDAC2), that tumors use as a “signal jammer” to prevent cancer cell death and evade the immune system’s functioning.
Recent work in The EMBO Journal describes a new hybrid post-translational modification of proteins, composed of a poly-ubiquitin chain that is attached to a target protein via a mono-ADP-ribose (MAR) ...
A study from Emory University suggests that levodopa, a medication that increases dopamine levels in the brain, may help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback